Skip to main content
Premium Trial:

Request an Annual Quote

Variagenics Appoints Four Directors for Pharmacogenomics

Premium

CAMBRIDGE, Mass.--Variagenics, a privately held venture-backed drug discovery technology company here, announced the appointment of four pharmacogenomics directors.

Mark Adams, previously the bioinformatics director for Alphagene, will be Variagenics' director of bioinformatics. Patrice Rioux, formerly medical director for Biogen, is Variagenics' new director of clinical pharmacogenomics. Troy Norris, also formerly of Biogen, where he was responsible for research and development program prioritization, is now senior director of business development for pharmacogenomics. And Andrew Ferrie joins Variagenics as director of variance detection from his former position as gene discovery manager at Human Genome Sciences.

"Variagenics' core competency is in the rapid discovery and analysis of genetic variation using our proprietary Variance Scanning and Variance Imaging technologies," said Fred Ledley, Variagenics' CEO. The appointments move the company toward its goal of applying genetic variation to the discovery and development of new pharmaceuitcal products, he said.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.